Zevra Therapeutics (KMPH) Stock Price, News & Analysis

Company Overview

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Key Stats

• Today's Range: N/A
• 50-Day Range: $4.48 to $6.27
• 52-Week Range: N/A
• Volume: 64,100 shs
• Average Volume: 189,500 shs
• Market Capitalization: $200.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KMPH Stock Analysis - Frequently Asked Questions

How were Zevra Therapeutics' earnings last quarter?

Zevra Therapeutics, Inc. (NASDAQ:KMPH) announced its quarterly earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). Zevra Therapeutics had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%.

When did Zevra Therapeutics IPO?

Zevra Therapeutics (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

What other stocks do shareholders of Zevra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Meta Platforms (META), SCYNEXIS (SCYX), BioCryst Pharmaceuticals (BCRX), Zoom Video Communications (ZM) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 3/30/2022
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KMPH
• CUSIP: N/A
• CIK: 1434647
• Web: www.kempharm.com
• Phone: (321) 939-3416
• Fax: 319-665-2577
• Employees: 22
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,560,000.00
• Net Margins: -328.56%
• Pretax Margin: -335.26%
• Return on Equity: -16.12%
• Return on Assets: -14.17%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 10.10
• Quick Ratio: 10.10

Sales & Book Value

• Annual Sales: $10.72 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 23.28
• Book Value: $3.63 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,505,000
• Free Float: 34,125,000
• Market Cap: $200.47 million
• Optionable: Optionable
• Beta: 2.16